NCT05169697

A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Eucure (Beijing) Biopharma Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	A:YH002+YH001	YH002 on CnD1,YH001 on CnD8,Q3W
DRUG	B:YH002+YH001	YH002 and YH001 on same day,Q3W
DRUG	YH002+YH001	A traditional 3+3 dose escalation algorithm

Timeline

• Start date: 2022-02-21
• Primary completion: 2023-07-04
• Completion: 2023-07-04
• First posted: 2021-12-27
• Last updated: 2025-01-06

Locations

9 sites across 2 countries: Australia, China